Insider buying last 90 days
No open-market insider purchases were filed for BEAM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BEAM insider filing, plotted on the chart in Gekko.Open BEAM in Gekko
NASDAQ: BEAM
Beam Therapeutics (BEAM) Stock Analysis & Forecast
Oct 12 close
$25.13−0.57 (−2.2%)
Gekko Brief
AI summaryOct 12 closeThis week's attention on Beam Therapeutics centers on safety and legal developments rather than financial results. A Pomerantz LLP investigation was disclosed following transient liver enzyme elevations reported in a Phase 1/2 trial of BEAM-302, which had previously triggered a notable share price decline. Separately, Beam filed a lawsuit against a former scientist and rival firm YolTech Therapeutics, alleging theft of trade secrets tied to its alpha-1 antitrypsin deficiency base-editing program. The company also appointed Eric Foster as Chief Commercial Officer to lead commercial strategy for its hematology and genetic disease candidates.
BEAM closed at $25.13, down 2.2%, sitting below both its 50-day average of $26.51 and its 200-day average of $28.43, with the shorter average also below the longer one, reflecting a broader downward trend. The GekkoIndex reads 57.9, placing it in the Neutral zone. Price stands 29.9% below Gekko Fair Value of $35.87.
Looking ahead, Beam reports earnings on 3 November 2026, before the open, falling within the next 20 trading days; its last report showed an EPS of -1.18 against a -1.11 estimate, with a 4.5% reaction. No insider, Congress, or unusual options activity in their respective windows was recorded. Seasonality over five years shows an average 20-day return of 1.2% from this point, with gains in 3 of those years. Consensus among 11 analysts stands at 10 buy, 1 hold, with a target of $52.15.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Beam Therapeutics price vs fair value
Close $25.13200-day averageGekko Fair Value $35.87
Beam Therapeutics quick facts
- Market cap
- $2.59B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.68
- Revenue, TTM
- $156.0M
- Profit margin
- -55.4%
- Dividend yield
- —
- Beta
- 2.20
- Volume
- 1.41M avg 1.91M
- 1-year return
- −9.8%
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±12%
- 50-day average
- $26.51
- 200-day average
- $28.43
- Next earnings
- Nov 3 before open
- Shares outstanding
- 103.3M
Beam Therapeutics swing-trade checklist
Beam Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $25.13 is below the 50-day ($26.51) and 200-day ($28.43) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
57.9, Neutral
Reading 57.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
29.9% below
Price is 29.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.2% on average
From this point in the calendar, the next 20 trading days averaged +1.2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Beam Therapeutics stock chart and price history
Beam Therapeutics closed at $25.13 on Oct 12, 2026, −9.8% over the past year, inside a 52-week range of $20.23 to $38.26.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +4.8%
- 3 months
- −18.6%
- 6 months
- −16.7%
- 1 year
- −9.8%
The full BEAM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BEAM in Gekko
Follow Beam Therapeutics through every session
Put BEAM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BEAM in GekkoFree for 7 days. No credit card required.
About Beam Therapeutics
Beam Therapeutics develops gene-editing treatments aimed at serious diseases, mainly for patients in the United States. Its work spans several candidates in development, including programs targeting sickle cell disease and beta thalassemia, a T-cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia, and a liver-directed treatment for Glycogen Storage Disease Type Ia. The company also pursues research into alpha-1 antitrypsin deficiency, eye conditions, and disorders affecting the liver, muscles, and nervous system.
Much of its progress depends on outside partnerships rather than working alone. Beam Therapeutics collaborates with Boston Children's Hospital, holds a research and clinical trial agreement with Magenta Therapeutics, and has licensed technology to Sana Biotechnology. It also works with the Institute of Molecular and Clinical Ophthalmology Basel on research, alongside separate research ties to Pfizer and Apellis Pharmaceuticals, and a broader collaboration and licensing arrangement with Verve Therapeutics.
The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker BEAM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- beamtx.com
Beam Therapeutics GekkoIndex: the smart money zone
Beam Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.9, in the Neutral zone, down 1.9 points over five sessions.
57.9Neutral
Down 1.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | −0.8% | +13.2% | ||
| Accumulation | 268 | +1.9% | +5.4% | ||
| Neutral (current zone) | 352 | +0.1% | −1.7% | ||
| Distribution | 26 | −6.9% | −8.0% | ||
| Selling | 1 | Too few readings yet | |||
Average BEAM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BEAM price, zone by zone.Track BEAM in Gekko
Is Beam Therapeutics stock overvalued? Gekko Fair Value
Beam Therapeutics trades 29.9% below Gekko Fair Value of $35.87, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Beam Therapeutics shares are worth, recalculated every trading day.
$35.87
Gekko Fair Value, Oct 10, 2026
29.9% Undervalued
At the end of Aug 2026 the price was 33.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open BEAM in Gekko
Beam Therapeutics insider and Congress trading
No open-market insider purchases were filed for Beam Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BEAM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BEAM, plotted on the chart in Gekko.Open BEAM in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds BEAM.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Beam Therapeutics earnings: next date and track record
Beam Therapeutics reports on Nov 3, 2026, before the open (22 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 22 days away
- EPS estimate
- −$1.15
- Revenue estimate
- $8.75M
4 of 8reports beat the EPS estimate
±6.9%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$1.18 est −$1.11 | $490K est $16.37M | +4.5% |
| May 7, 2026 | −$0.91 est −$1.01 | $31.74M est $10.98M | −0.1% |
| Feb 24, 2026 | $2.33 est −$1.01 | $114.1M est $11.67M | +4.5% |
| Nov 4, 2025 | −$1.10 est −$1.05 | $9.70M est $13.22M | −4.9% |
| Aug 5, 2025 | −$1.00 est −$1.11 | $8.47M est $11.54M | −4.3% |
| May 6, 2025 | −$1.24 est −$1.17 | $7.47M est $15.52M | −18.1% |
| Feb 25, 2025 | −$1.09 est −$1.22 | $30.07M est $16.47M | −9.4% |
| Nov 5, 2024 | −$1.17 est −$1.16 | $14.27M est $15.12M | +9.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Beam Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Beam Therapeutics is $52.15, +107.5% from the last close, from 11 firms rating the stock in the last 90 days.
$52.15consensus 12-month target, +107.5% from the last close
Now $25.13Avg $52.15
Low $26High $80
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | H.C. Wainwright | $80 | +218.3% |
| Sep 9 | Clear Street | $37 | +47.2% |
| Sep 9 | Canaccord Genuity | $78 | +210.4% |
| Sep 9 | Wedbush | $65 | +158.7% |
| Sep 9 | JonesTrading | $35 | +39.3% |
−1.7%average 20-day move after past Neutral readings
+1.2%average move over the next 20 trading days in the last 5 years
±5.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Beam Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Beam Therapeutics averaged +1.2% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.1% | 3 of 5 |
| Next 10 trading days | −1.7% | 2 of 5 |
| Next 15 trading days | −2.1% | 1 of 5 |
| Next 20 trading days | +1.2% | 3 of 5 |
| Next 30 trading days | +1.2% | 2 of 5 |
For scale, BEAM’s typical 20-trading-day move in either direction is about 12%.
Beam Therapeutics market cap and key statistics
Beam Therapeutics’s market cap is $2.59B and revenue of $156.0M over the last twelve months.
Valuation
- Market cap
- $2.59B
- EPS, TTM
- −$0.68
- Gekko Fair Value
- $35.87
Trading
- Volume
- 1.41M
- Avg volume, 20 days
- 1.91M
- 52-week high
- $38.26
- 52-week low
- $20.23
- Shares outstanding
- 103.3M
Financials
- Revenue, TTM
- $156.0M
- Profit margin
- -55.4%
- Return on equity
- -8.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.20
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±12%
Beam Therapeutics stock news this week
Coverage of Beam Therapeutics this week reads negative: 2 positive, 3 neutral and 3 negative headlines.
- (BEAM) Price Dynamics and Execution-Aware PositioningStock Traders Daily, Oct 10
- Beam Therapeutics (BEAM) Could Be 50% Undervalued As Probe Follows Trial Safety QuestionsSimply Wall Street, Oct 10
- Does Trade Secret Lawsuit Change The Bull Case For Beam Therapeutics Stock?Simply Wall Street, Oct 8
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPR Newswire, Oct 8
- Beam Therapeutics appoints Eric Foster as Chief Commercial OfficerPMLiVE, Oct 6
- Beam Therapeutics Sues Former Scientist for Alleged Theft of Gene-Editing Intellectual Property to Found Yoltech Therapeuticswww.geneonline.com, Oct 6
Beam Therapeutics peers
Beam Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Beam Therapeutics stock FAQ
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.59B at the Oct 12, 2026 close of $25.13, with 103.3M shares outstanding.
What is the Beam Therapeutics stock forecast?
The consensus analyst 12-month price target for Beam Therapeutics is $52.15, +107.5% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Beam Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Beam Therapeutics is undervalued: the Oct 12, 2026 close of $25.13 is 29.9% below Gekko Fair Value of $35.87. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Beam Therapeutics report earnings next?
Beam Therapeutics is expected to report on Nov 3, 2026, before the market opens (22 days away). Analysts expect earnings of −$1.15 per share on revenue of $8.75M. Beam Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 6.9% on average across the report.
What is Beam Therapeutics’s 52-week high and low?
Beam Therapeutics’s 52-week high is $38.26 and its 52-week low is $20.23; it closed at $25.13 on Oct 12, 2026, −9.8% over the past year. Over the last five years the shares peaked at $100.06 on Nov 9, 2021.
Is Beam Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Beam Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.